Preclinical CRO Accelera has teamed up with French biotech Cellectis to investigate a cancer therapy in the promising CAR-T class, treatments that use a patient's own T cells to attack tumors. The two plan to complete early-stage work on UCART19, Cellectis' preclinical treatment for B-cell leukemias and lymphomas, with Phase I trials planned for 2015. News